Cancer Care Ontario | Cancer Care Ontario

172 Results

Guidelines and Advice

Follow-up Care, Surveillance Protocols and Secondary Prevention Measures for Survivors of Colorectal Cancer

Status: Current
ID: GL 26-2
Version: 3

Mar 2021

Guidelines and Advice

Multiparametric Magnetic Resonance Imaging in the Diagnosis of Clinically Significant Prostate Cancer

Status: Current
ID: GL 27-2
Version: 2

Feb 2021

Guidelines and Advice

Combined Modality Radiotherapy and Chemotherapy in the Non-surgical Management of Localized Carcinoma of the Esophagus

Status: Education and Information
ID: 2-12
Version: 2

Oct 2013

Guidelines and Advice

Organizational Guideline for Gynecologic Oncology Services in Ontario

Status: In-Review
ID: 4-11

Jun 2013

Guidelines and Advice

An Endorsement of the 2021 Guideline on Chemotherapy in Combination with Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline

Status: Current
ID: GL END 5-7
Version: 3

Nov 2021

Guidelines and Advice

The Use of Imatinib Mesylate (GleevecTM) in Patients with Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

Status: Archived
ID: CED 10

Sep 2008

Guidelines and Advice

Docetaxel plus Cyclophosphamide as Adjuvant Therapy for Early, Operable Breast Cancer

Status: Archived
ID: CED 9

Aug 2008

Guidelines and Advice

The Use of Chemotherapy and Growth Factors in Older Patients with Newly Diagnosed, Advanced Stage, Aggressive Histology Non-Hodgkin's Lymphoma

Status: Education and Information
ID: 6-7 Version 2
Version: 2

Jun 2013

Guidelines and Advice

Altered Fractionation of Radical Radiation Therapy in the Management of Unresectable Non-Small Cell Lung Cancer

Status: Education and Information
ID: 7-12 Version 2
Version: 2

May 2013

Guidelines and Advice

The Use of Epidermal Growth Factor Receptor Inhibitors in Advanced Colorectal Cancer

Status: Archived
ID: CED 8

Jul 2008

Guidelines and Advice

Sorafenib for Advanced Hepatocellular Carcinoma

Status: Archived
ID: CED 7

Feb 2008

Guidelines and Advice

The Prognostic Value of the DNMT3A Biomarker in Cytogenetically Normal Patients with Acute Myeloid Leukemia

Status: Archived
ID: MOAC 1

Nov 2013

Follow-up Care, Surveillance Protocols and Secondary Prevention Measures for Survivors of Colorectal Cancer

Multiparametric Magnetic Resonance Imaging in the Diagnosis of Clinically Significant Prostate Cancer

Combined Modality Radiotherapy and Chemotherapy in the Non-surgical Management of Localized Carcinoma of the Esophagus

Organizational Guideline for Gynecologic Oncology Services in Ontario

An Endorsement of the 2021 Guideline on Chemotherapy in Combination with Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline

The Use of Imatinib Mesylate (GleevecTM) in Patients with Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

Docetaxel plus Cyclophosphamide as Adjuvant Therapy for Early, Operable Breast Cancer

The Use of Chemotherapy and Growth Factors in Older Patients with Newly Diagnosed, Advanced Stage, Aggressive Histology Non-Hodgkin's Lymphoma

Altered Fractionation of Radical Radiation Therapy in the Management of Unresectable Non-Small Cell Lung Cancer

The Use of Epidermal Growth Factor Receptor Inhibitors in Advanced Colorectal Cancer

Sorafenib for Advanced Hepatocellular Carcinoma

The Prognostic Value of the DNMT3A Biomarker in Cytogenetically Normal Patients with Acute Myeloid Leukemia

Pages